Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Mirum Pharmaceuticals reports robust Q2 performance and eyes strategic growth

Mirum Pharmaceuticals showcased strong financial performance, strategic progress, and a focus on innovation during the Q2 2023 earnings call.
The company's emphasis on pediatric hepatology, upcoming acquisitions, and commitment to bringing important medicines to patients globally position it for future success.
While facing challenges such as regulatory strategies and integration post-acquisition, Mirum has opportunities to drive growth through product expansion and market leadership.

Mirum Pharmaceuticals reports strong Q3 revenue and strategic acquisitions

Mirum Pharmaceuticals demonstrated solid performance in Q3 2023 with strong revenue and strategic acquisitions.
While facing challenges such as net losses and high operating expenses, the company maintains a strong financial position.
Opportunities lie in upcoming milestones, product commercialization, and financial optimization under new leadership.
Overall, Mirum Pharmaceuticals shows promise for growth and innovation in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q4 earnings and growth opportunities

Mirum Pharmaceuticals delivered strong financial results in Q4 2023, with significant revenue growth and net product sales.
Despite operating expenses and a net loss, the company remains well-funded and poised for growth in 2024.
Key milestones and progress in pipeline development highlight Mirum's commitment to innovation and market expansion.
Balancing financial performance with pipeline advancement and regulatory milestones will be crucial for Mirum's sustained success in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q1 sales growth and pipeline advancements

Mirum Pharmaceuticals demonstrated strong sales growth and financial stability in Q1 2024, driven by the success of LIVMARLI and advancements in product pipeline.
While facing challenges in managing expenses and navigating a competitive market, Mirum's focus on rare liver disease treatments presents significant opportunities for growth.
The company's commitment to innovation, gratitude for stakeholders, and strategic plans for NDA submissions underscore a promising outlook for future success.
Investors should monitor Mirum's progress in commercializing key products and expanding its market reach to capitalize on the growth potential in rare disease treatments.

Mirum Pharmaceuticals excels in Q2, eyes global expansion and innovation

Mirum Pharmaceuticals demonstrated impressive growth and achieved key milestones in Q2 2024, positioning the company for future success.
While facing challenges such as net losses and market competition, Mirum's strengths in product innovation and market expansion offer opportunities for sustained growth.
By focusing on cost management, regulatory compliance, and strategic partnerships, Mirum can navigate challenges and capitalize on opportunities to drive long-term value for stakeholders.

Mirum Pharmaceuticals excels in Q3, raises revenue guidance and expands pipeline

Mirum Pharmaceuticals delivered exceptional results in Q3 2024, showcasing strong financial performance, robust commercial programs, and promising pipeline advancements. With increased revenue guidance, breakthrough designations, and positive cash flow, the company is well-positioned for continued success. Challenges lie in maintaining growth momentum amidst competition and regulatory complexities, but opportunities for expansion and innovation abound.

Mirum Pharmaceuticals excels in 2024, poised for global growth

Mirum Pharmaceuticals showcased strong financial performance, exceeding sales targets and achieving cash flow positivity in 2024. The company's focus on global growth, pipeline advancement, and financial discipline sets a solid foundation for sustained success. While facing challenges such as market uncertainties and strategic execution, Mirum is well-positioned to leverage opportunities for growth and innovation.

Mirum Pharmaceuticals excels in Q1 with revenue surge and regulatory wins

Mirum Pharmaceuticals delivered impressive revenue growth, updated guidance, and key regulatory milestones in Q1 2025, reflecting a strong performance and growth trajectory. While facing challenges in expense management and study timelines, Mirum's strategic strengths lie in innovation, product development, and financial stability. The company's focus on operational efficiency, clinical advancements, and market opportunities sets the stage for sustained growth and value creation for stakeholders.

Mirum Pharmaceuticals excels in Q2 2025, projects strong revenue growth

Mirum Pharmaceuticals demonstrated robust financial performance, highlighted by significant revenue growth and positive cash flow, while also showcasing advancements in its pipeline and strategic confidence. The company faces challenges in addressing analyst queries on therapy persistence rates and revenue distribution but stands to benefit from opportunities in market expansion and pipeline development. Overall, Mirum Pharmaceuticals' Q2 2025 earnings call reflects a promising outlook with strong revenue projections, pipeline progress, and strategic optimism.

Mirum Pharmaceuticals excels in Q3 with revenue surge and R&D progress

Mirum Pharmaceuticals showcased strong financial and operational performance in Q3 2025, marked by revenue growth, positive net income, and progress in R&D pipeline. The company's focus on patient-centric approaches and strategic advancements position it well for future growth and innovation.

Mirum Pharmaceuticals excels in Q4 2025, poised for growth

Mirum Pharmaceuticals delivered robust financial performance, strong cash position, and promising pipeline advancements in Q4 2025. While facing challenges such as rising R&D expenses and maintaining profitability margins, Mirum is well-positioned for growth and market expansion. The company's focus on innovation, commercial execution, and financial discipline underscores its potential for sustained success and value creation.

Mirum Pharmaceuticals reports robust Q1 earnings and expands treatment offerings

Mirum Pharmaceuticals showcased strong financial performance and product efficacy in Q1 2026, with a positive outlook for the full year. While facing challenges such as increased R&D expenses and managing recent acquisitions, the company remains well-positioned for growth. Opportunities lie in expanding rare liver disease treatments, accelerating market entry for new products, and leveraging a solid financial foundation.